21,683 Shares in AxoGen, Inc. $AXGN Bought by EntryPoint Capital LLC

Key Points

• EntryPoint Capital LLC has invested approximately $401,000 in AxoGen, Inc. by acquiring 21,683 shares during the first quarter.
• AxoGen's stock has seen significant interest from institutional investors, with 80.29% of the company's stock now owned by these investors.
• Research analysts have upgraded AxoGen's stock, giving it an average "Buy" rating and a consensus price target of $26.00.

EntryPoint Capital LLC bought a new stake in AxoGen, Inc. (NASDAQ:AXGN - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 21,683 shares of the medical equipment provider's stock, valued at approximately $401,000.

A number of other large investors also recently made changes to their positions in AXGN. LPL Financial LLC acquired a new position in shares of AxoGen in the 4th quarter valued at about $210,000. Wells Fargo & Company MN grew its holdings in AxoGen by 26.0% during the fourth quarter. Wells Fargo & Company MN now owns 32,760 shares of the medical equipment provider's stock valued at $540,000 after purchasing an additional 6,753 shares during the last quarter. Renaissance Technologies LLC acquired a new position in AxoGen during the fourth quarter valued at approximately $363,000. Raymond James Financial Inc. acquired a new position in AxoGen during the fourth quarter valued at approximately $4,552,000. Finally, Barclays PLC grew its holdings in AxoGen by 6.9% during the fourth quarter. Barclays PLC now owns 77,003 shares of the medical equipment provider's stock valued at $1,269,000 after purchasing an additional 4,967 shares during the last quarter. Institutional investors and hedge funds own 80.29% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Wall Street Zen upgraded AxoGen from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Canaccord Genuity Group lowered their price target on AxoGen from $26.00 to $24.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $26.00.

AxoGen Stock Performance

Shares of AXGN traded up $0.42 during mid-day trading on Friday, hitting $16.26. The company's stock had a trading volume of 1,001,771 shares, compared to its average volume of 1,941,713. AxoGen, Inc. has a one year low of $9.22 and a one year high of $21.00. The company has a debt-to-equity ratio of 0.59, a quick ratio of 2.67 and a current ratio of 4.14. The firm has a market capitalization of $748.12 million, a PE ratio of -162.58 and a beta of 1.00. The stock's 50-day moving average is $12.38 and its two-hundred day moving average is $14.47.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.